On May 4, 2026, Mirum Pharmaceuticals, Inc. reported that their VISTAS Phase 2b study for volixibat met its primary endpoint, showing a significant average 2.72 point improvement in pruritus in patients with primary sclerosing cholangitis (PSC). This study included 158 patients and is expected to lead to a New Drug Application (NDA) submission in the second half of 2026.